Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform

Nature Biotechnology

Volumn 15, Issue 12, 1997, Pages 1271-1275

  Neri, Dario ^a,b   Carnemolla, Barbara ^c   Nissim, Ahuva ^a,d   Leprini, Alessandra ^c   Querzè, Germano ^c   Balza, Enrica ^c   Pini, Alessandro ^e   Tarli, Lorenzo ^b   Halin, Cornelia ^b   Neri, Paolo ^d   Zardi, Luciano ^c   Winter, Greg ^a  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF GENOA   (Italy)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^e UNIVERSITY OF SIENA   (Italy)

Author keywords

Antibody engineering; Oncofetal protein; Single chain antibody

Indexed keywords

FIBRONECTIN; MONOCLONAL ANTIBODY; ONCOFETAL ANTIGEN;

ANGIOGENESIS; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ARTICLE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; TERATOCARCINOMA; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; DNA PRIMERS; FIBRONECTINS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT PROTEINS; TERATOCARCINOMA;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 0030700632     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt1197-1271     Document Type: Article

References (46)

1. Berkower, I. 1996. The promise and pitfalls of monoclonal antibody therapeutics. Curr. Opin. Biotechnol. 7:622-628.
2. Press, O.W., Eary, J.F., Appelbaum, F.R., Martin, P.J., Nelp, W.B., Glen, S., et al. 1995. Phase II trial of 1311-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346:336-340.
3. Riva, P., Arista, A., Tison, V., Sturiale, C., Franceschi, G., Spinelli, A., et al. 1994. Intralesional radio-immunotherapy of malignant gliomas. Cancer 73:1076-1082.
4. Schneider-Gadicke, E. and Riethmüller, G. 1995. Prevention of manifest metastasis with monoclonal antibodies: a novel approach to immunotherapy of solid tumors. Eur. J. Cancer 31:1326-1330.
5. Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., and Levy, R. 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84:2457-2466.
6. Winter, G., Griffiths, A.D., Hawkins, R.E., and Hoogenboom, H.R. 1994. Making antibodies by phage display technology. Annu. Rev. Immunol. 12:433-455.
7. Carter, P., Kelley, R.F., Rodrigues, M.L., Snedecor, B., Covarrubias, M., Velligan, M.D., et al. 1992. High level Escherichia coli expression and production of a bivalent humanized antibody fragment. Bio/Technology 10:163-167.
8. Pack, R, Kujau, M., Schroeckh, U., Knüpfer, R., Wenderoth, R., Riesenberg, D., and Plückthun, A. 1993. Improved bivalent miniantibodies with identical avidity as whole antibodies produced by high cell density fermentation of Escherichia coli. Bio/Technology 11:1271-1277.
9. Begent, R.H.J., Verhaar, M.J., Chester, K.A., Green, A.J., Napier, M.P., Hope-Stone, L.D., et al. 1996. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nature Medicine 2:979-984.
10. Casey, J.L., Keep, P.A., Chester, K.A., Robson, L., Hawkins, R.E., and Begent, R.H. 1995. Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography. J. Immunol. Methods 179:105-116.
11. Yokota, T., Milenic, D.E., Whitlow, M., and Schlom, J. 1992. Rapid tumor penetration of single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52:3402-3408.
12. Pasqualini, R., Koivunen, E., and Ruoslahti, E. 1997. Alfa-v integrins as receptors for tumor targetin by circulating ligands. Nature Biotechnology 15:542-546.
13. Kim, K.J., Li, B., Winer, J., Armanii, M., Gillett, N., Phillips, H.S., and Ferrara, N. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362:841-844.
14. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumathoid and other disease. Nature Med. 1:27-31.
15. O’Reilly, M.S., Holmgren, L., Chen, C., and Folkman, J. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2:689-692.
16. Huang, H., Molema, G., King, S., Watkins, L., Edgington, T.S., and Thorpe, P.E. 1997. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor neo-vasculature. Science 275:547-550.
17. Van den Hoff, A. 1988. Stromal involvement in malignant growth. Adv. Cancer Res. 50:159-196.
18. Risau, W. and Lemmon, V. 1988. Changes in the vascular extracellular matrix during embryonic vasculogenesis and angiogenesis. Dev. Biol. 125:441-450.
19. Carnemolla, B., Balza, E., Siri, A., Zardi, L., Nicotra, M.R., Bigotti, A., and Natali, P.G. 1989. A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J. Cell Biol. 108:1139-1148.
20. Castellani, P., Viale, G., Dorcaratto, A., Nicolo, G., Kazmarek, J., Querze, G., and Zardi, L. 1994. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int. J. Cancer 59:612-618.
21. Carnemolla, B., Neri, D., Castellani, P., Leprini, A., Neri, G., Pini, A., et al. 1996. Phage antibodies with pan-species recognition of the oncofetal angiogenesis marker fibronectin ED-B domain. Int. J. Cancer 68:397-405.
22. Huston, J.S., Levinson, D., Mudgett, H.M., Tai, M.S., Novotny, J., Margolies, M.N., et al. 1988. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85:5879-5883.
23. Bird, R.E., Hardman, K.D., Jacobson, J.W., Johnson, S., Kaufman, B.M., Lee, S.M., et al. 1988. Single-chain antigen-binding proteins. Science 242:423-426.
24. Nissim, A., Hoogenboom, H.R., Tomlínson, I.M., Flynn, G., Midgley, C, Lane, D., and Winter, G. 1994. Antibody reagents from a ‘single-pot’ phage display library as immunochemical reagents. EMBO J. 13:692-698.
25. Marks, J.D., Griffiths, A.D., Malmqvist, M., Clackson, TP., Bye, J.M., and Winter, G. 1992. By-passing immunization: building high-affinity human antibodies by chain shuffling. Bio/Technology 10:779-783.
26. Low, N., Holliger, P., and Winter, G. 1996. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol. 260:359-368.
27. Griffiths, A.D., Williams, S.C., Hartley, O., Tomlinson, I.M., Waterhouse, P., Crosby, W.L., et al. 1994. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13:3245-3260.
28. Vaughan, T.J., Williams, A.J., Pritchard, K., Osbourn, J.K., Pope, A.R., Earnshaw, J.C., et al. 1996. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnology 14:309-314.
29. Folli, S., Westermann, P., Braichotte, D., Pelegrin, A., Weignieres, G., van der Bergh, H., and Mach, J.P. 1994. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res. 54:2643-2649.
30. Neri, D., Prospero, T, Petrul, H., Winter, W., Browne, M., and Vanderpant, L. 1996. A multi-purpose high-sensitivity luminescence analyser (LUANA): use in gel electrophoresis. Bio/Techniques 20:708-713.
31. Friedlander, M., Theesfeld, C.L., Sugita, M., Fruttiger, M., Thomas, M.A., Chang, S., and Cheresh, D.A. 1996. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA 93:9764-9769.
32. Adams, G.P., McCartney, J.E., Tai, M.S., Oppermann, H., Huston, J.S., Stafford W.F. III, et al. 1993. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB2 sincle-chain Fv. Cancer Res. 53:4026-4034.
33. King, D.J., Turner, A., Farnsworth, A.P.H., Adair, J.R., Owens, R.J., Pedley, R.B., et al. 1994. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res. 54:6176-6185.
34. Hu, S., Shively, L, Raubitschek, A., Sherman, M., Williams, L.E., Wong, J.Y., et al. 1996. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56:3055-3061.
35. Peters, J.H., Chen, G., and Hynes, R.O.1996. Fibronectin isoform distribution in the mouse. II. Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse. Cell Adhes. Commun. 4:127-148.
36. Bennett, V.D., Pallante, K.M., and Adams, S.L. 1991. The splicing pattern of fibronectin mRNA changes during chondrogenesis resulting in an unusual form of the mRNA in cartilage. J. Biol. Chem. 266:5918-5924.
37. George, A.J., Jamar, F., Tai, M.S., Heelan, B.T., Adams, G.R, McCartney, J.E., et al. 1995. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc. Natl. Acad. Sci. USA 92:8358-8362.
38. Liberatore, M., Neri, D., Neri, G., Pini, A., lurilli, A.P., Ponzo, F., et al. 1995. Efficient one-step direct labeling of recombinant antibodies with 99mTc. Eur. J. Nuclear Med. 22:1326-1329.
39. Neri, D. and Zardi, L. 1997. New approaches to tumor targeting, in Therapy of malignancies with radio-conjugate monoclonal antibodies: present possibilities and future perspectives. Riva P. (ed.) Harwood Academic Publishers, Amsterdam, The Netherlands. In press.
40. Padlan, E.A. 1994. Anatomy of the antibody molecule. Mol. Immunol. 31:169-217.
41. Marks, J.D., Hoogenboom, H.R., Bonnert, TP, McCafferty, J., Griffiths, A.D., and Winter, G. 1991. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222:581-597.
42. Hoogenboom, H.R., Griffiths, A.D., Johnson, K.S., Chiswell, D.J., Hudson, R, and Winter, G. 1991. Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. Nucl. Acids Res. 19:4133-4137.
43. Gibson, T.J. 1984. Studies on the Epstein-Barr virus genome. Ph.D. Thesis, University of Cambridge, Cambridge, UK.
44. Jönsson, U., Fägerstam, L., Ivarsson, B., Johnsson, B., Karlsson, R., Lundh, K., et al. 1991. Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. BioTechniques 11:620-627.
45. Neri, D., Petrul, H., Light, Y, Marais, R., Britton, K.E., Winter, G., and Creighton, A.M. 1996. Radioactive labeling of recombinant antibody fragments by phosphorylation using human casein kinase II and [γ-32P]-ATP. Nature Biotechnology 14:385-390.
46. McCafferty, J., Griffiths, A.D., Winter, G., and Chiswell, D.J. 1990. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552-554.